There are two ways to look at a month. On a calendar, it is a rectangle divided into smaller rectangles. In addiction treatment, it can be a succession of tasks: take the medicine, keep the appointment, arrange the next prescription. Indivior has built much of its future around changing one part of that routine. Its monthly buprenorphine injection, Sublocade, moves medication delivery out of a daily ritual and into a clinical appointment. The interesting feature is time.
- Sublocade supplied about 69% of Indivior's 2025 net revenue.
- The company has pulled back from promoting two other medicines.
- A proposed Supernus merger has shareholder approval, with closing expected November 2.
A month, measured in daily decisions
Indivior sells prescription medicines for opioid use disorder, a condition it describes as a chronic, treatable brain disease. Its older product, Suboxone Film, combines buprenorphine and naloxone in a film absorbed in the mouth. Sublocade contains extended-release buprenorphine. A healthcare professional administers it under the skin; the patient does not leave with a month's supply of daily doses.
That difference changes the work involved in treatment. It can remove daily medication handling. It still requires access to a clinician, an appointment and a way to pay. The medicine is intended for moderate to severe opioid use disorder within a treatment program that includes counseling and psychosocial support. A different schedule can lighten one burden while leaving several others intact.
In February 2025, the FDA approved a change that addressed another stretch of waiting. Eligible patients could begin Sublocade after a single dose of transmucosal buprenorphine and observation to confirm tolerability, replacing the previous week-long initiation requirement. This was a change to the route into treatment, as well as the treatment itself. Starting still requires clinical assessment and monitoring.
For someone exploring treatment, the Sublocade patient website offers a provider finder and information to discuss with a healthcare professional. This is a route into a clinical conversation, rather than a direct purchase. Sublocade is maintenance treatment; an overdose-reversal medicine serves a different purpose. Understanding that distinction matters when a company has sold products for both ongoing care and emergencies.
A business built around the calendar
The corporate story begins inside Reckitt, which established a buprenorphine business group in 1994. Indivior became independent through a demerger in December 2014. There is no garage-founder origin to excavate. It inherited an operating pharmaceutical business, then had to build a future as its established products faced competition.
Sublocade won U.S. approval in 2017 and became available in 2018. By 2025, it generated $856 million of Indivior's $1.239 billion net revenue. The company had become increasingly dependent on getting one particular treatment format into more clinics. In the second quarter of 2026, total Sublocade revenue reached $253 million, up 21% from the same quarter a year earlier.
of revenue came from Sublocade
The end user is a person seeking treatment. The commercial customer may be a wholesaler, specialty pharmacy or distributor. Government programs and commercial insurers help determine access and reimbursement. That makes Indivior's expertise broader than formulation: clinical evidence, controlled-drug distribution and payer negotiations all sit between a medicine and the person who needs it.
Its monthly format also has company. Braeburn's Brixadi, approved by the FDA in 2023, offers weekly and monthly injections. Generic buprenorphine-naloxone products compete with Suboxone. The choice involves clinical suitability, dosing preferences and access. A monthly interval is a useful distinction; it does not establish that one product is right for every patient.
The expensive art of narrowing down
The first conspicuous retreat in the recent portfolio came in July 2024. Indivior stopped sales and marketing for Perseris, its injectable schizophrenia medicine. Management pointed to competition and expected payer restrictions that made the product's future financially unviable. The announcement anticipated roughly 130 job reductions and about $65 million in charges, including approximately $20 million in cash costs.
Then came OPVEE. Indivior acquired its developer, Opiant, in March 2023 for $146 million upfront, with potential additional milestone payments. The nalmefene nasal spray received approval for emergency opioid-overdose reversal that year. By July 2024, Indivior was reporting adoption behind expectations. It discontinued sales and marketing support in the third quarter of 2025.
Approval opens a door. Adoption decides whether a business can stay in the room.
Those decisions distinguish two problems that pharmaceutical optimism can blur. A medicine can gain regulatory approval and still face a difficult commercial market. A product can attract investment and still fail to earn continued promotional support. These were commercial retreats, not declarations that the medicines lacked therapeutic activity.
Joe Ciaffoni, appointed chief executive in May 2025, subsequently pursued a narrower organization and a greater emphasis on Sublocade. The practical lesson another business can borrow is to examine the recurring burden on the user, then test the delivery system around the solution. Better frequency needs workable purchasing, staffing and distribution.
The past stays in the room
A profile of Indivior also has to account for its marketing history. In 2020, Indivior Solutions pleaded guilty to a felony involving false statements, and Indivior entities agreed to pay $600 million to resolve criminal and civil liability associated with Suboxone marketing. That record belongs alongside the company's current language about integrity.
Indivior describes compassion, science and reducing stigma as cultural priorities. It supports organizations including Mobilize Recovery, Shatterproof and the INTO LIGHT Project. These collaborations extend into advocacy, education and portraits of people lost to addiction. They show what the company supports; they do not erase its legal history or independently establish its workplace culture.
The next appointment
On October 15, 2026, Indivior shareholders approved its proposed all-stock merger with Supernus. The company expects closing on November 2 and says the combined business will operate as Supernus, Inc. As of this profile's October 22 publication date, completion remains ahead.
The corporate name may change. The product question persists: can a different treatment routine help people remain in care? Monthly delivery offers one answer. Its usefulness depends on clinical fit, access and continuity. The calendar is part of the solution. Getting someone to the next appointment remains part of the work. For a reader outside pharmaceuticals, that is the revealing detail: a product can simplify what happens between visits without simplifying the institution that delivers it. The useful question is which task has disappeared, who has taken on the remaining tasks, and whether that arrangement can last.